Nike Appoints Former Pfizer CFO David Denton as Finance Chief

Nike (NKE) announced the appointment of David Denton, former CFO of Pfizer, as its new chief financial officer, succeeding Matthew Friend who left in April. The company also reaffirmed its financial guidance for fiscal 2026, but provided no concrete evidence that its turnaround plan is gaining traction.

Background of David Denton

David Denton served as Pfizer's CFO from 2021 to 2024, overseeing the company's finances during a period of strong growth driven by COVID-19 vaccine revenues. He previously held senior finance roles at Honeywell. Denton brings extensive experience in managing the finances of major global corporations.

Reasons for the Change

Former CFO Matthew Friend left in April 2026 shortly after Nike announced a restructuring plan aimed at cutting costs and boosting innovation. The company did not specify a reason for his departure but stated that the new appointment is part of efforts to strengthen its leadership team.

Impact on the Company

Analysts believe Denton's appointment could provide financial stability as Nike faces challenges in the Chinese market and slowing demand in North America. However, the new CFO's impact on the turnaround may not be visible for several quarters.

Market Reaction

Nike's stock showed little movement following the announcement, closing at $85.40, up just 0.3%. This reflects investor caution as they await clearer signs of a successful transformation.